References

Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients

10.1002/14651858.cd003961.pub2 · ExternalCitation · doi-reference

Cyclosporin versus tacrolimus for liver transplanted patients

10.1002/14651858.cd005161.pub2 · ExternalCitation · doi-reference

Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients

10.1002/14651858.cd008817.pub2 · ExternalCitation · doi-reference

Antibody induction therapy for lung transplant recipients

10.1002/14651858.cd008927.pub2 · ExternalCitation · doi-reference

Early extracorporeal photopheresis treatment is associated with better survival in patients with chronic or recurrent acute lung allograft dysfunction

10.1002/jca.22128 · ExternalCitation · doi-reference

Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American college of clinical pharmacy, American society of transplantation, and international society for heart and lung transplantation: an executive summary

10.1002/phar.2718 · ExternalCitation · doi-reference

Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials

10.1007/s00228-010-0902-6 · ExternalCitation · doi-reference

Clinical trial of tacrolimus versus cyclosporine in lung transplantation

10.1016/0003-4975(95)00407-c · ExternalCitation · doi-reference

A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation

10.1016/j.healun.2007.07.027 · ExternalCitation · doi-reference

The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation

10.1016/j.healun.2009.08.029 · ExternalCitation · doi-reference

Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation

10.1016/j.healun.2012.03.008 · ExternalCitation · doi-reference

A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation

10.1016/j.healun.2012.05.002 · ExternalCitation · doi-reference

Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction

10.1016/j.healun.2017.03.017 · ExternalCitation · doi-reference

Bronchiolitis obliterans syndrome-free survival after lung transplantation: an international society for heart and lung transplantation thoracic transplant registry analysis

10.1016/j.healun.2018.09.016 · ExternalCitation · doi-reference

Montelukast in chronic lung allograft dysfunction after lung transplantation

10.1016/j.healun.2018.11.014 · ExternalCitation · doi-reference

Azithromycin and early allograft function after lung transplantation: a randomized, controlled trial

10.1016/j.healun.2018.12.006 · ExternalCitation · doi-reference

Chronic lung allograft dysfunction: definition and update of restrictive allograft syndrome-A consensus report from the pulmonary council of the ISHLT

10.1016/j.healun.2019.03.008 · ExternalCitation · doi-reference

Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-A consensus report from the pulmonary council of the ISHLT

10.1016/j.healun.2019.03.009 · ExternalCitation · doi-reference

The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-Sixth adult lung and heart-lung transplantation Report-2019; focus theme: donor and recipient size match

10.1016/j.healun.2019.08.001 · ExternalCitation · doi-reference

Influence of azithromycin and allograft rejection on the post–lung transplant microbiota

10.1016/j.healun.2019.11.007 · ExternalCitation · doi-reference

Azithromycin prophylaxis after lung transplantation is associated with improved overall survival

10.1016/j.healun.2020.09.006 · ExternalCitation · doi-reference

Once daily tacrolimus conversion in lung transplantation: a prospective study on safety and medication adherence

10.1016/j.healun.2021.02.017 · ExternalCitation · doi-reference

Assessing treatment outcomes in CLAD: the hannover-extracorporeal photopheresis model

10.1016/j.healun.2022.09.022 · ExternalCitation · doi-reference

Randomized controlled trial comparing immediate versus extended release tacrolimus; reducing calcineurin inhibitor related toxicity in lung transplantation patients; the revolution trial

10.1016/j.healun.2024.02.071 · ExternalCitation · doi-reference

Results from randomized trial of pirfenidone in patients with chronic rejection (STOP-CLAD study)

10.1016/j.healun.2024.05.013 · ExternalCitation · doi-reference

Impact of tacrolimus vs cyclosporine on chronic lung allograft dysfunction incidence and allograft survival in the international society of heart and lung transplantation registry

10.1016/j.healun.2024.10.013 · ExternalCitation · doi-reference

Considerations for endpoints in lung transplant clinical trials: an ISHLT consensus statement

10.1016/j.healun.2025.09.017 · ExternalCitation · doi-reference

A boxed warning for montelukast: the FDA perspective

10.1016/j.jaip.2021.02.057 · ExternalCitation · doi-reference

GRADE guidelines: 2. Framing the question and deciding on important outcomes

10.1016/j.jclinepi.2010.09.012 · ExternalCitation · doi-reference

GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes

10.1016/j.jclinepi.2012.01.006 · ExternalCitation · doi-reference

GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations

10.1016/j.jclinepi.2012.03.013 · ExternalCitation · doi-reference

GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions

10.1016/j.jclinepi.2019.10.014 · ExternalCitation · doi-reference

Impact of reduced mycophenolate exposure on chronic lung allograft dysfunction incidence after lung transplant

10.1016/j.jhlto.2024.100156 · ExternalCitation · doi-reference

Mycophenolate mofetil reduces alveolar inflammation, acute rejection and graft loss due to bronchiolitis obliterans syndrome after lung transplantation

10.1016/j.pupt.2010.04.004 · ExternalCitation · doi-reference

Initiation of extracorporeal photopheresis in lung transplant patients with mild to moderate refractory BOS: a single-center real-life experience

10.1016/j.resmer.2022.100913 · ExternalCitation · doi-reference

Outcomes in lung transplant recipients on azathioprine compared to mycophenolate

10.1016/j.rmed.2025.107991 · ExternalCitation · doi-reference

Peripheral CD4+CD25+ TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients

10.1016/j.transproceed.2006.10.227 · ExternalCitation · doi-reference

Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients

10.1016/j.transproceed.2013.09.026 · ExternalCitation · doi-reference

Effectiveness of rabbit antithymocyte globulin in chronic lung allograft dysfunction

10.1016/j.transproceed.2016.04.024 · ExternalCitation · doi-reference

Efficacy of extracorporeal photopheresis in patients with bronchiolitis Obliterans syndrome after lung transplantation

10.1016/j.transproceed.2017.02.035 · ExternalCitation · doi-reference

Outcomes following extracorporeal photopheresis for chronic lung allograft dysfunction following lung transplantation: a single-center experience

10.1016/j.transproceed.2020.09.003 · ExternalCitation · doi-reference

Antithymocyte globulin treatment for chronic lung allograft dysfunction in lung transplant recipients: experience from a national reference transplant center

10.1016/j.transproceed.2021.08.039 · ExternalCitation · doi-reference

Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: an update

10.1016/j.trim.2015.04.003 · ExternalCitation · doi-reference

Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis

10.1016/s0022-5223(99)70241-2 · ExternalCitation · doi-reference

Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols

10.1016/s1053-2498(01)00244-3 · ExternalCitation · doi-reference

Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation

10.1016/s1053-2498(99)00004-2 · ExternalCitation · doi-reference

Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): a multicentre randomised controlled trial

10.1016/s2213-2600(23)00293-x · ExternalCitation · doi-reference

Impact of SLCO1B3 polymorphisms on clinical outcomes in lung allograft recipients receiving mycophenolic acid

10.1038/s41397-019-0086-0 · ExternalCitation · doi-reference

Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation

10.1046/j.1600-6135.2003.00260.x · ExternalCitation · doi-reference

Nerandomilast in patients with idiopathic pulmonary fibrosis

10.1056/nejmoa2414108 · ExternalCitation · doi-reference

Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial

10.1067/mtc.2003.71 · ExternalCitation · doi-reference

Pharmacogenetics of mycophenolate mofetil: a promising different approach to tailoring immunosuppression?

10.1093/joneph/21.4.503 · ExternalCitation · doi-reference

A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation

10.1097/00007890-199403270-00013 · ExternalCitation · doi-reference

Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation

10.1097/00007890-199602150-00019 · ExternalCitation · doi-reference

Optimization of the immunosuppressive protocol after lung transplantation

10.1097/00007890-199907150-00013 · ExternalCitation · doi-reference

Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection1

10.1097/00007890-200106270-00012 · ExternalCitation · doi-reference

Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients

10.1097/01.tp.0000202755.33883.61 · ExternalCitation · doi-reference

Factors associated with mortality and response to extracorporeal photopheresis in lung allograft recipients with bronchiolitis obliterans syndrome

10.1097/tp.0000000000002430 · ExternalCitation · doi-reference

Lung transplant outcomes in adults in the United States: retrospective cohort study using real-world evidence from the SRTR

10.1097/tp.0000000000004011 · ExternalCitation · doi-reference

Extracorporeal photopheresis after lung transplantation: a 10-Year single-center experience

10.1097/tp.0b013e31818bc024 · ExternalCitation · doi-reference

Outcomes following ATG therapy for chronic lung allograft dysfunction

10.1097/txd.0000000000001134 · ExternalCitation · doi-reference

Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients

10.1111/ajt.12155 · ExternalCitation · doi-reference

Prophylactic azithromycin therapy after lung transplantation: post hoc analysis of a randomized controlled trial

10.1111/ajt.13417 · ExternalCitation · doi-reference

Lung

10.1111/ajt.13671 · ExternalCitation · doi-reference

Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis

10.1111/ajt.13863 · ExternalCitation · doi-reference

Pirfenidone in restrictive allograft syndrome after lung transplantation: a case series

10.1111/ajt.15019 · ExternalCitation · doi-reference

Rescue alemtuzumab for refractory acute cellular rejection and bronchiolitis obliterans syndrome after lung transplantation

10.1111/ctr.12899 · ExternalCitation · doi-reference

Lung transplant recipients on long‐term extracorporeal photopheresis

10.1111/ctr.13041 · ExternalCitation · doi-reference

Rabbit antithymocyte globulin for the treatment of chronic lung allograft dysfunction

10.1111/ctr.13708 · ExternalCitation · doi-reference

Early onset of azithromycin to prevent CLAD in lung transplantation: promising results of a retrospective single centre experience

10.1111/ctr.14832 · ExternalCitation · doi-reference

Anti-thymocyte globulin as a therapy for chronic lung allograft dysfunction: a single-center experience

10.1111/ctr.15461 · ExternalCitation · doi-reference

Multicenter, real‐world clinical evaluation of Alemtuzumab and anti‐thymocyte globulin for severe acute T cell‐mediated kidney transplant rejection

10.1111/ctr.70046 · ExternalCitation · doi-reference

Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations

10.1111/j.1398-9995.2010.02530.x · ExternalCitation · doi-reference

Airway cellular response to two different immunosuppressive regimens in lung transplant recipients

10.1111/j.1399-0012.2005.00330.x · ExternalCitation · doi-reference

Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study

10.1111/j.1432-2277.2011.01248.x · ExternalCitation · doi-reference

Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation

10.1111/j.1600-6143.2007.02000.x · ExternalCitation · doi-reference

Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction

10.1111/tme.12779 · ExternalCitation · doi-reference

The efficacy of extracorporeal photopheresis to arrest bronchiolitis obliterans in lung allograft recipients was compared between two automated photopheresis instruments

10.1111/trf.14913 · ExternalCitation · doi-reference

Outcomes with alemtuzumab induction therapy in lung transplantation: a comprehensive large‐scale single‐center analysis

10.1111/tri.14153 · ExternalCitation · doi-reference

Lymphocyte depleting and modulating therapies for chronic lung allograft dysfunction

10.1124/pharmrev.123.000834 · ExternalCitation · doi-reference

Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases Antimicrob agents chemother

10.1128/aac.02067-13 · ExternalCitation · doi-reference

GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction

10.1136/bmj.i2016 · ExternalCitation · doi-reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1136/bmj.n71 · ExternalCitation · doi-reference

Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK)

10.1136/bmjresp-2023-001995 · ExternalCitation · doi-reference

Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis

10.1136/bmjresp-2024-002672 · ExternalCitation · doi-reference

Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial

10.1136/thorax-2022-219391 · ExternalCitation · doi-reference

Pharmacogenomics and individualized drug therapy

10.1146/annurev.med.56.082103.104724 · ExternalCitation · doi-reference

Clinical investigations long-term off-line extracorporeal photochemotherapy in patients with chronic lung allograft rejection not responsive to conventional treatment: a 10-Year single-centre analysis

10.1159/000431382 · ExternalCitation · doi-reference

Follow-Up care after adult lung transplantation: summary of an evidence-based clinical practice guideline for german-speaking countries

10.1159/000553086 · ExternalCitation · doi-reference

A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation

10.1183/09031936.00068310 · ExternalCitation · doi-reference

Extracorporeal photopheresis for the prevention of rejection after lung transplantation: a prospective randomised controlled trial

10.1183/13993003.00733-2024 · ExternalCitation · doi-reference

ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults

10.1183/13993003.01727-2023 · ExternalCitation · doi-reference

A European multi-center, randomized controlled trial of Pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation

10.1183/13993003.02154-2024 · ExternalCitation · doi-reference

Immune processes in the pathogenesis of chronic lung allograft dysfunction: identifying the missing pieces of the puzzle

10.1183/16000617.0060-2022 · ExternalCitation · doi-reference

Chronic lung allograft dysfunction after lung transplantation: prevention, diagnosis and treatment in 44 European centres

10.1183/23120541.00675-2024 · ExternalCitation · doi-reference

Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant

10.1371/journal.pone.0160421 · ExternalCitation · doi-reference

Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a randomized controlled trial

10.1371/journal.pone.0193564 · ExternalCitation · doi-reference

Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation

10.1378/chest.109.4.874 · ExternalCitation · doi-reference

Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation

10.1378/chest.115.5.1459 · ExternalCitation · doi-reference

Pirfenidone in chronic lung allograft dysfunction: a single cohort study

10.23736/s0031-0808.19.03840-0 · ExternalCitation · doi-reference

Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus

10.3346/jkms.2010.25.12.1759 · ExternalCitation · doi-reference

Comparison of Alemtuzumab and anti-thymocyte globulin treatment for acute kidney allograft rejection

10.3389/fimmu.2020.01332 · ExternalCitation · doi-reference

Antithymocyte globulin therapy in chronic lung allograft dysfunction

10.3389/frtra.2025.1607678 · ExternalCitation · doi-reference

A European multi-center analysis of extracorporeal photopheresis as therapy for chronic lung allograft dysfunction

10.3389/ti.2023.11551 · ExternalCitation · doi-reference

A decade of experience with alemtuzumab therapy for severe or glucocorticoid-resistant kidney transplant rejection

10.3389/ti.2023.11834 · ExternalCitation · doi-reference